Enables several functions, including ADP-D-ribose modification-dependent protein binding activity; oxidized DNA binding activity; and poly-ADP-D-ribose binding activity. Involved in several processes, including DNA repair; positive regulation of single strand break repair; and voluntary musculoskeletal movement. Located in nucleolus and nucleoplasm. Part of chromatin. Is active in site of DNA damage. Implicated in several diseases, including artery disease (multiple); carcinoma (multiple); central nervous system cancer (multiple); gastrointestinal system cancer (multiple); and hematologic cancer (multiple). Biomarker of liver cancer.
DNA repair protein XRCC1; RCC; SCAR26; X-ray repair complementing defective repair in Chinese hamster cells 1; x-ray repair cross-complementing group 1 protein; X-ray repair cross-complementing protein 1; X-ray-repair, complementing defective, repair in Chinese hamster
Dexrazoxane inhibits the reaction [Idarubicin results in decreased expression of XRCC1 mRNA] and Dexrazoxane inhibits the reaction [Idarubicin results in decreased expression of XRCC1 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of XRCC1 mRNA
NIPBL mRNA alternative form promotes the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of XRCC1 protein]
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of XRCC1 mRNA and 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in decreased expression of XRCC1 protein
[Fenretinide results in increased abundance of Reactive Oxygen Species] which results in decreased expression of XRCC1 protein and Ascorbic Acid inhibits the reaction [Fenretinide results in decreased expression of XRCC1 protein]
Decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of XRCC1 mRNA] and Decitabine inhibits the reaction [Cadmium Chloride results in decreased expression of XRCC1 protein]
XRCC1 protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with Cisplatin] and XRCC1 protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]
XRCC1 protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with Cisplatin] and XRCC1 protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]
Acetylcysteine inhibits the reaction [XRCC1 gene mutant form results in decreased abundance of Adenosine Triphosphate] and Acetylcysteine promotes the reaction [XRCC1 protein results in increased abundance of Adenosine Triphosphate]
[Benzo(a)pyrene co-treated with 1-methylphenanthrene] affects the expression of XRCC1 mRNA and [Benzo(a)pyrene co-treated with fluoranthene] affects the expression of XRCC1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of XRCC1 mRNA
GSTM1 gene polymorphism affects the reaction [XRCC1 gene polymorphism affects the reaction [Vinyl Chloride affects the mutagenesis of TP53 gene]] more ...
XRCC1 mutant form results in increased susceptibility to chromium hexavalent ion and XRCC1 protein polymorphism results in increased susceptibility to chromium hexavalent ion
[Cisplatin results in decreased susceptibility to Cisplatin] which results in increased expression of XRCC1 mRNA and XRCC1 protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with Cisplatin]
[Clofibrate co-treated with Acetaminophen] affects the expression of XRCC1 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of XRCC1 mRNA]
Curcumin inhibits the reaction [Arsenic results in decreased expression of XRCC1 mRNA] and Curcumin inhibits the reaction [Arsenic results in decreased expression of XRCC1 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of XRCC1 mRNA
Dexrazoxane inhibits the reaction [Idarubicin results in decreased expression of XRCC1 mRNA] and Dexrazoxane inhibits the reaction [Idarubicin results in decreased expression of XRCC1 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of XRCC1 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 mRNA] and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Etoposide results in increased expression of XRCC1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased stability of XRCC1 mRNA and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased stability of XRCC1 protein
Acetylcysteine inhibits the reaction [XRCC1 gene mutant form results in increased abundance of Malondialdehyde] and Acetylcysteine promotes the reaction [XRCC1 protein results in decreased abundance of Malondialdehyde]
[Clofibrate co-treated with Acetaminophen] affects the expression of XRCC1 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of XRCC1 mRNA]
[Fenretinide results in increased abundance of Reactive Oxygen Species] which results in decreased expression of XRCC1 protein and Ascorbic Acid inhibits the reaction [Reactive Oxygen Species results in decreased expression of XRCC1 protein]
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in increased expression of XRCC1 protein
The X-ray repair cross complementing protein 1 (XRCC1) rs25487 polymorphism and susceptibility to cirrhosis in Brazilian patients with chronic viral hepatitis.
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.
Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer.
Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma.
XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
[The influence of XRCC1 gene polymorphism on the prognosis and safety of stage Ⅲ patients with colorectal cancer who received oxaliplatin based adjuvant chemotherapy].
Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population.
Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.
Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
Polymorphisms of XRCC1 and XRCC2 DNA Repair genes and Interaction with Environmental Factors Influence the Risk of Nasopharyngeal Carcinoma in Northeast India.
Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) Polymorphisms in Familial and Sporadic Breast Cancer Predisposition and Survival: An Indian Report.
The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo)radiotherapy in patients with nasopharyngeal carcinoma.
Roles of XRCC1/XPD/ERCC1 Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization.
[Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
The association between four SNPs of X-ray repair cross complementing protein 1 and the sensitivity to radiotherapy in patients with esophageal squamous cell carcinoma.